Cargando…
Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
BACKGROUND: Introduction of biologic disease-modifying antirheumatic drugs (DMARDs) has revolutionized treatment in patients with rheumatoid arthritis (RA). However, due to substantially higher costs of biologics compared with nonbiologics, patients with less insurance generosity may have difficulty...
Autores principales: | Desai, Rishi J., Rao, Jaya K., Hansen, Richard A., Fang, Gang, Maciejewski, Matthew L., Farley, Joel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441023/ https://www.ncbi.nlm.nih.gov/pubmed/25351972 http://dx.doi.org/10.18553/jmcp.2014.20.11.1110 |
Ejemplares similares
-
Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Reams, Jennifer, et al.
Publicado: (2020) -
Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005) -
Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
por: Park, Siyeon, et al.
Publicado: (2019) -
Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study
por: Kang, Eun Ha, et al.
Publicado: (2018) -
Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)